Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial Robert J. MotzerPaul RussoAxel Bex Summary of research Open access 02 September 2023 Pages: 639 - 641
Mutant HRas Signaling and Rationale for Use of Farnesyltransferase Inhibitors in Head and Neck Squamous Cell Carcinoma Jiayu WangDana Al-MajidJoshua D. Smith Review Article 04 September 2023 Pages: 643 - 655
Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study Kenji MorimotoTadaaki YamadaKoichi Takayama Original Research Article 23 August 2023 Pages: 657 - 665
Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1 Xin MiaoLiviawati S. WuSuzette Girgis Original Research Article Open access 15 September 2023 Pages: 667 - 684
Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma Lan-Hsi LinMohammad GhasemiAndrew K. L. Goey Original Research Article 26 August 2023 Pages: 685 - 695
Comparative Effectiveness of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in the Post-Platinum Setting: A Real-World Canadian Synthetic Control Arm Analysis Devon J. BoyneDavid E. DaweWinson Y. Cheung Original Research Article 01 September 2023 Pages: 697 - 705
Real-World Treatment Sequencing in Vulnerable Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Study Seiichiro MitaniYosuke KitoHisato Kawakami Original Research Article 05 September 2023 Pages: 707 - 715
Impact of Cardiovascular Comorbidities on the Effectiveness and Safety of Bevacizumab in Older Patients with Metastatic Colorectal Cancer Amandine GouverneurClélia FavaryPernelle Noize Original Research Article 08 September 2023 Pages: 717 - 726
Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences Jacqueline C. BarrientosAyed O. AyedJing-Zhou Hou Original Research Article Open access 20 September 2023 Pages: 727 - 734
Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients Scott JewSean BujarskiJames R. Berenson Original Research Article 08 September 2023 Pages: 735 - 747
Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6) Hanno M. WitteJörg RiedlNiklas Gebauer Original Research Article Open access 24 July 2023 Pages: 749 - 765
A Retrospective Analysis of Biliary Tract Cancer Patients Presented to the Molecular Tumor Board at the Comprehensive Cancer Center Munich Danmei ZhangKlara DormanC. Benedikt Westphalen Original Research Article Open access 18 August 2023 Pages: 767 - 776
FDA Approvals of Oncology Drugs for Tissue-Agnostic Indications Marjorie E. Zettler Original Research Article 21 July 2023 Pages: 777 - 792
Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer Arnold Lee Adis Drug Evaluation Open access 05 August 2023 Pages: 793 - 800
Correction to: Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer Arnold Lee Correction Open access 16 September 2023 Pages: 801 - 801
